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Background: The aim of this study was characterization of an updated distribution of CFTR mutations in a representative cohort of 40 CF patients
with the classical form of the disease drawn from Eastern Hungary. Due to the homogeneity of the Hungarian population our data are generally
applicable to other regions of the country, including the sizeable diaspora.
Methods: We utilized the recommended “cascade” CFTR mutation screening approach, initially using a commercial assay, followed by
examination of the common “Slavic” deletion CFTRdele2,3(21 kb). Subsequently, the entire CFTR coding region of the CFTR gene was
sequenced in patients with yet unidentified mutations.
Results: The Elucigene CF29Tm v2 assay detected 81.25% of all CF causing mutations. An addition of the CFTRdele2,3(21 kb) increased the
mutation detection rate to 86.25%. DNA sequencing enabled us to identify mutations on 79/80 CF alleles. Mutations [CFTRdele2,3(21 kb),
p.Gln685ThrfsX4 (2184insA) were found at an unusually high frequency, each comprising 5.00% of all CF alleles.
Conclusion: We have identified common CF causing mutations in the Hungarian population with the most common mutations (p.Phe508del,
p.Asn1303Lys, CFTRdele2,3(21 kb), 2184insA, p.Gly542X, and p.Leu101X), comprising over 93.75% of all CF alleles. Obtained data are
applicable to the improvement of DNA diagnostics in Hungary and beyond, and are the necessary prerequisite for the introduction of a nationwide
“two tier” CF newborn screening program.
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More than 1600 sequence alterations have been reported in
the cystic fibrosis transmembrane conductance regulator
(CFTR) gene, among which less than 20 mutations display
clear ethnic and geographic affiliation. To date, three previous
publications regarding the prevalence of a limited number of
CFTR mutations in Hungary [1–3] are available, however the
most recent being from 1996.
The aim of this study is to provide updated data on the
distribution of CFTR gene mutations in a representative cohortd by Elsevier B.V. All rights reserved.
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fibrosis (CF). Due to the population homogeneity in Hungary
our results can be of utility for the entire Hungarian population,
including the sizeable (approximately 2 million) Hungarian
diaspora. We hope that our data will enable development of a
screening panel optimized for the CF mutation distribution and
foster introduction of newborn screening.
2. Methods
Diagnosis of CF was established on the basis of standard
consensus clinical and laboratory criteria [4]. Sweat chloride
concentrations were measured using a Sweat Chek Conductivity
Analyzer (Wescor, USA) and/or using the Sanasol Sweat
Analyzer (Sanasol, Hungary). Altogether 40 unrelated CF
patients were included (mean age±SD; 14.4±8.7 years). The
geographical origin of studied patients and their families is
shown in Fig. 1.
DNA isolation from blood leukocytes was performed using a
commercial system (QIAgen BloodMini Kit, Qiagen, Germany).
Three different approaches, in accordancewith updated European
recommendations [5], were used for the identification of the
common European CF-causing mutations: a/ initially Elucigene
CF29Tm v2Kit, Tepnel Diagnostics, UKwas utilized, b/ followed
by the examination of the common “Slavic”CFTRdele2,3(21 kb)
deletion [6] and finally c/ patients with unidentified CF muta-
tions were subjected to sequencing of the entire coding region
of CFTR gene [7], except that for exon 6b modified primers
were used— 6BF (5′-CTG TAC AGC GTC TGG CAC AT-3′)
and 6BR (5′-CAA ACA TCA AAT ATG AGG TGG AA-3′).
The Elucigene CF29Tm v2 Kit is capable of detecting the
following mutations: p.Asp1152His (c.3454 GNC), c.1585-
1 GNA, p.Gly542X (c.1624 GNT), p.Trp1282X (c.3846 GNA),
p.Asn1303Lys (c.3909 C NG), p.Phe508del (c.1521_
1523delCTT), c.3717+12191 CNT, p.Leu88IlefsX22 (c.262_
263delTT), c.489+1 GNT, p.Ser1251Asn (c.3752 GNA),
p.Gly551Asp (c.1652 GNA), p.Arg117His (c.350 GNA),
p.Arg1162X (c.3484 CNT), p.Arg334Trp (c.1000 CNT),
p.Ala455Glu (c.1364 CNA), p.Lys684SerfsX38 (c.2051_Fig. 1. Origin of the patients2052delAAinsG), p.Lys1177SerfsX15 (c. 3528delC), p.Phe316-
LeufsX12 (c.948delT), p.Ile507del (c.1519_1521delATC),
p.Arg347Pro (c.1040 GNC), p.Arg553X (c.1657 CNT),
p.Glu60X (c.178 GNT), c.2988+1 GNA, c.2657+5 GNA,
c.1766+1 GNA, c.579+1 GNT, p.Gly85Glu (c.254 GNA),
c.p.Lys684AsnfsX38 (c.2052delA), and p.Arg560Thr (c.1679
GNC). ForDNA sequencing the PCRproducts were cleaned using
ultra-filtration micro-columns (Microcon YM-100, Millipore,
USA). Purified PCR products were sequenced using BigDye
Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems,
USA). Removal of unincorporated nucleotides was performed
using gel filtration (DyeEx Kit, Qiagen). Capillary electrophoresis
was performed on the ABI Prism 310 Genetic Analyzer (Applied
Biosystems). Intragenic CFTR rearrangements were examined by
multiplex ligation-dependent probe amplification (MLPA)-
SALSA MLPA KIT P091-B1 CFTR (MRC-Holland, The
Netherlands). With regards to mutation nomenclature we used
the commonly used “legacy name” followed by the currently
recommended description in parentheses (Table 1).3. Results
The mean sweat chloride concentration was 108 mmol/L,
ranging 55–173 mmol/L (in line with the manufacturer's
specifications), with all but one patient having concentrations
over 60 mmol/L. With the Elucigene CF29Tm v2 assay we
identified the p.Phe508del mutation on 56/80 CF alleles
(70.00%), p.Asn1303Lys (4x; 5.00%), p.Gly542X (3x;
3.75%), 1717-1 GNA and pArg347Pro (1x each; 1.25%). The
CFTRdele2,3(21 kb) mutation was present on 4 CF alleles
(5.00%). Only one mutant allele could be detected in 11
samples. Therefore these were analyzed further by sequencing:
in 4 patients the presence of p.Gln685ThrfsX4 (2184insA)
(5.00%) was revealed. Two patients had the p.Leu101X
(2.50%) mutation, while the remainder bore p.Gln220X,
p.Ser466X, p.Tyr1092X, and p.Glu831X alleles (one each;
1.25%). In one patient, no other CF causing mutation was
found.included in this study.
Table 1
Comparison of CFTR mutation distribution in selected Central European populations.
CFTR mutation Germany 1994 Romania 2008 Austria 1997 Slovakia 2008 Hungary 1992 This study
deltaF508 (c.1521_1523 delCTT) 72.0% 56.3% 74.6% 38.2% 64.3% 70.0%
G551D (c.1652 GNA) 1.0% N/F 1.6% N/F N/F N/F
R553X (c.1657 CNT) 2.3% N/F N/F 1.2% 2.4% N/F
G542X (c.1624 GNT) 1.4% 3.9% 2.4% 2.4% 1.2% 3.75%
621+1 GNT (c.489+1 GNT) 0.1% 0.8% N/F N/F N/F N/F
1717-1 GNA (c.1585-1 GNA) 0.9% N/F 0.8% 0.6% 1.2% 1.25%
W1282X (c.3846 GNA) 0.7% 2.3% N/F N/F 1.2% N/F
N1303K (c.3909 CNG) 2.3% 0.8% N/F 1.2% 1.2% 5.0%
R347P (c.1040 GNC) 1.6% N/F 1.6% 1.2% N/A 1.25%
CFTRdele2,3(21 kb) 1.5%a 1.6% 2.6%a 1.1%a N/A 5.0%
2184insA (c.2052_2053 insA) 0.6% N/F N/F 2.4% N/A 5.0%
L101X (c.302 TNG) N/F N/F N/F N/F N/A 2.5%
Q220X (c.658 CNT) N/F N/F N/F N/F N/A 1.25%
S466X (c.1397 CNG) N/F N/F N/F N/F N/A 1.25%
E831X (c.2491 GNT) N/F N/F N/F 0.6% N/A 1.25%
Y1092X (c.3276 CNA) 0.3% N/F N/F N/F N/A 1.25%
Legend: data for Germany [8], Romania [9], Austria [10], Slovakia [11] and Hungary [3]; N/A: not analyzed; N/F: not found, afrequencies reported by Dork et al. in
2000 [6], mutations included in the Elucigene CF29 v2 assay are formatted in italics; the original “legacy name” is followed by the recommended mutation
nomenclature [17].
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of the mutation phase was performed in their respective
families, with all detected mutations present in trans. Only
one tested case remained with p.Phe508del together with an
unidentified allele in trans, with CFTR rearrangement analysis
by MLPA being negative. The population distribution of
mutations detected in this study was compared to German [8],
Romanian [9], Austrian [10], Slovakian [11] and previous
Hungarian [3] studies as shown in Table 1.
4. Discussion
Hereby, we present the first comprehensive study of CFTR
mutation distribution in the Eastern Hungarian population
which complements decade old partial studies of this subject
[1–3]. Given the homogeneity of the general Hungarian
population, based on previous population genomic studies
showing relatively “small spread” within principle component-
based analyses [12–15], data drawn from Eastern Hungary are
very likely relevant for the remainder of the country. At present,
there are approximately 10 million citizens living in Hungary.
According to the Official Gazette of the Ministry of Health
(2008) the prevalence for cystic fibrosis is 1:4000 in Hungary.
The Eastern part of Hungary is neighboring Slovakia, Ukraine
and Romania, with approximately 2 million inhabitants.
Population admixture increased when subsequently Romanian
shepherds, Flemmish and Slovakian settlers colonized this
region. According to a local survey from 1910 the population
reported to be of 54.5% Hungarian, 16.1% Romanian, 10.7%
Slovakian, and 10.2% German origin, including several other
minorities. However, Romani origin was not reported at that
time. We use this survey for illustration, since self-reporting of
ethnicity substantially changed during the last century, when
over 94% of the inhabitants had declared to be of Hungarian
origin in 2001.In general the observed degree of mutation heterogeneity is
between the reported Northern and Southern European mutation
spectra [16], whereby all mutations were previously detected in
South German, Ashkenazi Jewish and other Balkans popula-
tions [17] and filed in the Cystic Fibrosis Mutation Database
[17]. Altogether six mutations reached a higher prevalence than
1.30%: p.Phe508del, p.Asn1303Lys, CFTRdele2,3(21 kb),
2184insA, p.Gly542X and p.Leu101X, in decreasing order of
their frequencies. As the population under study is not primarily
of Slavic origin, it is interesting, that the Slavic mutation
CFTRdele2,3(21 kb) was found on 5.00% of CF alleles, which
is the third highest prevalence after Czech Republic (6.37%)
and Russia (5.69%) [6]. In this respect Eastern Hungary was
formerly inhabited by Slavic tribes who later gradually
assimilated with Hungarians (from 895 AD), which likely
explains the high frequency of this allele.
The 2184insA frameshift mutation was found at a particularly
high frequency (5.00%). In this regard a recent paper of Makukh
et al. (2010) [18] reported that this allele is the second most
common mutation in Western Ukraine, comprising 7.20% of all
mutated CF alleles. Since Western Ukraine is bordering the area
from which our cohort was drawn (Fig. 1.), this result shows
population relatedness of both regions given their close long-
term historical ties. Therefore, our data confirm the “Galician
origin” of this mutation [18] given its decreasing gradient
towards the region from which our patients were drawn. It will
be of interest to study similar cohorts of CF patients in
neighboring Eastern Slovakia, Southeastern Poland, Belarus
and Northwestern Romania in order to further substantiate this
likely regional founder effect.
For the analysis ofmutations in the cohort under studywe used
the recommended “cascade approach” [5,19] analyzing common
mutations first followed by sequencing and rearrangement
analysis as specified in the Methods section. Thus, when using
the Tepnel CF29Tm v2 assay 81.25% of CF-causing mutations
Table 2
Increasing detection rate using the cascade screening strategy in the Eastern
Hungarian CF population.
Detected CF alleles
Number %
Elucigene CF 29Tm v2 assay 65 81.25%
Elucigene CF 29 Tm v2 assay+CFTRdele2,3(21 kb)a 69 86.25%
Elucigene CF 29 Tm v2 assay+CFTRdele2,
3(21 kb)a+2184insAb+L101Xb
75 93.75%
DNA sequencing of the remaining CFTR exons 79 98.75%
Legend:
a“Junction PCR“ method [6].
bIdentified by targeted sequencing of CFTR exons 13 and 4.
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mutation increased the detection rate to 86.25%. Sequencing
was essential for the detection of the unexpectedly highly
prevalent mutation 2184insA (Table 2).
In total, we identified 98.75% of the CF causing mutations in
Eastern Hungarians in line with other CF populations which
were thoroughly investigated by the set of techniques utilized in
this study [20] and where only patients with the classical form
of the disease where included. In the case of the only remaining
patient, the most likely explanation is that an intronic or
promoter mutation which was not analyzed by our methods
might be producing the null allele.
In summary, we present a CFTR mutation panel which could
be used in DNA diagnostics in the entire Hungarian population.
Moreover, since there is a substantial Hungarian diaspora of
2 millions [21] living in neighboring countries and North
America, our data are pertinent to these populations as well. The
observed mutation spectrum is in line with previous Central
European studies [16]. Finally, our study will serve as the
necessary prerequisite for the introduction of nation-wide “two
tier” (IRT/DNA) newborn screening programs [22].
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